KANAGAWA, JAPAN – August 4th, 2020
PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(Tokyo:4587) today announced that it has entered into a strategic partnership with San Diego, California, US – based RayzeBio Inc., (“RayzeBio”) for the discovery and development of peptide-radioisotope (RI) conjugates for use as therapeutics (“Peptide Radiotherapeutics”).
Under the agreement, the two companies will work on a number of programs against targets mutually agreed to, with PeptiDream providing peptide candidates, identified and optimized using its proprietary Peptide Discovery Platform System (PDPS) technology, to RayzeBio for further development as radiotherapeutics, with RayzeBio holding exclusive worldwide development and commercialization rights to the program peptides for use with radioisotopes. PeptiDream will lead preclinical discovery and optimization efforts, with RayzeBio leading translational biology efforts to further characterize peptide-RI conjugates and advance such conjugates into clinical development and commercialization activities.
Under the terms of the agreement, PeptiDream will receive an equity interest in RayzeBio, as well as be eligible for certain payments associated with product development and commercial success, as well as royalties on future sales of any products that arise from the partnership.
This strategic partnership with RayzeBio, in addition to existing partnerships with Nihon Medi Physics (2018) and Novartis (2019), solidifies PeptiDream’s position as a leader in the Peptide Radiotherapeutics field.
“We are truly excited to announce this new strategic partnership with RayzeBio for the discovery and development of novel and innovative Peptide Radiotherapeutics. With RayzeBio leading translational biology, development and commercialization and PeptiDream focused on the preclinical discovery and optimization, we think this partnership with RayzeBio can further enable (or accelerate) PeptiDream’s goal of bringing several first-in-class and best-in-class radiotherapeutics to patients worldwide.” said Patrick C. Reid PhD, President & CEO of PeptiDream.
PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit www.peptidream.com.
Mie Yamazaki IR & Public Affairs – (Kanagawa)